Prognostic Factors in Renal Cell Carcinoma

Seminars in Oncology

Volumn 33, Issue 5, 2006, Pages 563-575

  Shuch, Brian M ^a   Lam, John S ^a   Belldegrun, Arie S ^a   Figlin, Robert A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL FEATURE; DATA ANALYSIS; HUMAN; KIDNEY CARCINOMA; MEDICAL LITERATURE; MOLECULAR DYNAMICS; PARANEOPLASTIC SYNDROME; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOSIS; TUMOR VOLUME;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33749631580     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.06.006     Document Type: Article

References (123)

1. Jemal A., Siegal R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Lam J.S., Leppert J.T., Figlin R.A., et al. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep 6 (2005) 7-18
3. Guinan P., Sobin L.H., Algaba F., et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80 (1997) 992-993
4. Giuliani L., Giberti C., Martorana G., et al. Radical extensive surgery for renal cell carcinoma: Long-term results and prognostic factors. J Urol 143 (1990) 468-473
5. Kontak J.A., and Campbell S.C. Prognostic factors in renal cell carcinoma. Urol Clin North Am 30 (2003) 467-480
6. Hafez K.S., Fergany A.F., and Novick A.C. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 162 (1999) 1930-1933
7. Lerner S.E., Hawkins C.A., Blute M.L., et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol 155 (1996) 1868-1873
8. Sobin L.H., and Wittekind C. TNM Classification of Malignant Tumours. (ed 6). (2002), Wiley-Liss, New York, NY 193
9. Patard J.J., Shvarts O., Lam J.S., et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 171 (2004) 2181-2185
10. Leibovich B.C., Blute M.L., Cheville J.C., et al. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 171 (2004) 1066-1070
11. Frank I., Blute M.L., Leibovich B.C., et al. Independent validation of the 2002 American Joint Committee on Cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 173 (2005) 1889-1892
12. Cheville J.C., Blute M.L., Zincke H., et al. Stage pT1 conventional (clear cell) renal cell carcinmoa: Pathological features associated with cancer specific survival. J Urol 166 (2001) 453-456
13. Ficarra V., Guille F., Schips L., et al. Proposal for revision of the TNM classification system for renal cell carcinoma. Cancer 104 (2005) 2116-2123
14. Tsui K.H., Shvarts O., Smith R.B., et al. Prognostic indicators for renal cell carcinoma: A multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 163 (2000) 1090-1095
15. Frank I., Blute M.L., Leibovich B.C., et al. pT2 classification for renal cell carcinoma. Can its accuracy be improved?. J Urol 173 (2005) 380-384
16. Lam J.S., Patard J.J., Goel R.H., et al. Can pT2 classification for renal cell carcinoma be improved?. An international multicenter experience. J Urol 175 suppl (2006) 240-241
17. Lam J.S., Patard J.J., Goel R.H., et al. Significance of tumor size in locally advanced renal cell carcinoma (pT3a): An international multicenter experience. J Urol 175 suppl (2006) 234
18. Han K.R., Bui M.H., Pantuck A.J., et al. TNM T3a renal cell carcinoma: Adrenal gland involvement is not the same as renal fat invasion. J Urol 169 (2003) 899-903
19. Thompson R.H., Leibovich B.C., Cheville J.C., et al. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a?. J Urol 173 (2005) 918-921
20. Thompson R.H., Cheville J.C., Lohse C.M., et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer 104 (2005) 53-60
21. Lam J.S., Patard J.J., Leppert J.T., et al. Prognostic significance of T3a renal cell carcinoma with adrenal gland involvement: an international multicenter experience. J Urol 173 suppl (2005) 269-270
22. Thompson R.H., Leibovich B.C., Cheville J.C., et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?. J Urol 174 (2005) 1218-1221
23. Leibovich B.C., Cheville J.C., Lohse C.M., et al. Cancer specific survival for patients with pT3 renal cell carcinoma-Can the 2002 primary tumor classification be improved?. J Urol 173 (2005) 716-719
24. Kim H.L., Zisman A., Han K.R., et al. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different?. J Urol 171 (2004) 588-591
25. Moinzadeh A., and Libertino J.A. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same?. J Urol 171 (2004) 598-601
26. Blute M.L., Leibovich B.C., Lohse C.M., et al. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int 94 (2004) 33-41
27. Pantuck A.J., Zisman A., Dorey F., et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 97 (2003) 2995-3002
28. Pantuck A.J., Zisman A., Dorey F., et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 169 (2003) 2076-2083
29. Vasselli J.R., Yang J.C., Linehan W.M., et al. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 166 (2001) 68-72
30. Waters W.B., and Richie J.P. Aggressive surgical approach to renal cell carcinoma: Review of 130 cases. J Urol 122 (1979) 306-309
31. Studer U.E., Scherz S., Scheidegger J., et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 144 (1990) 243-245
32. Lam J.S., Belldegrun A.S., and Figlin R.A. Advances in immune-based therapies of renal cell carcinoma. Expert Rev Anticancer Ther 4 (2004) 1081-1096
33. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Lancet 353 (1999) 14-17
34. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655-1659
35. Mickisch G.H., Garin A., van Poppel H., et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet 358 (2001) 966-970
36. Flanigan R.C., Mickisch G., Sylvester R., et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis. J Urol 171 (2004) 1071-1076
37. Montie J.E., Stewart B.H., Straffon R.A., et al. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 117 (1977) 272-275
38. Marcus S.G., Choyke P.L., Reiter R., et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 150 (1993) 463-466
39. Dekernion J.B., Ramming K.P., and Smith R.B. The natural history of metastatic renal cell carcinoma: A computer analysis. J Urol 120 (1978) 148-152
40. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
41. Neves R.J., Zincke H., and Taylor W.F. Metastatic renal cell cancer and radical nephrectomy: Identification of prognostic factors and patient survival. J Urol 139 (1988) 1173-1176
42. Figlin R., Gitlitz B., Franklin J., et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am 3 suppl 1 (1997) S92-S97
43. Mani S., Todd M.B., Katz K., et al. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 154 (1995) 35-40
44. Seaman E., Goluboff E.T., Ross S., et al. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. Urology 48 (1996) 692-695
45. Han K.R., Pantuck A.J., Bui M.H., et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 61 (2003) 314-319
46. Fuhrman S.A., Lasky L.C., and Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6 (1982) 655-663
47. Bretheau D., Lechevallier E., de Fromont M., et al. Prognostic value of nuclear grade of renal cell carcinoma. Cancer 76 (1995) 2543-2549
48. Storkel S., Eble J.N., Adlakha K., et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80 (1997) 987-989
49. Chao D., Zisman A., Pantuck A.J., et al. Collecting duct renal cell carcinoma: Clinical study of a rare tumor. J Urol 167 (2002) 71-74
50. Davis Jr. C.J., Mostofi F.K., and Sesterhenn I.A. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 19 (1995) 1-11
51. Delahunt B., Eble J.N., McCredie M.R., et al. Morphologic typing of papillary renal cell carcinoma: Comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 32 (2001) 590-595
52. Yang X.J., Tan M.H., Kim H.L., et al. A molecular classification of papillary renal cell carcinoma. Cancer Res 65 (2005) 5628-5637
53. Amin M.B., Tamboli P., Javidan J., et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol 26 (2002) 281-291
54. Cheville J.C., Lohse C.M., Zincke H., et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27 (2003) 612-624
55. Patard J.J., Leray E., Rioux-Leclercq N., et al. Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. J Clin Oncol 23 (2005) 2763-2771
56. Motzer R.J., Bacik J., Mariani T., et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20 (2002) 2376-2381
57. Upton M.P., Parker R.A., Youmans A., et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 28 (2005) 488-495
58. Farrow G.M., Harrison Jr. E.G., and Utz D.C. Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. Cancer 22 (1968) 556-563
59. Goldstein N.S. The current state of renal cell carcinoma grading. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80 (1997) 977-980
60. Cangiano T., Liao J., Naitoh J., et al. Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 17 (1999) 523-528
61. de Peralta-Venturina M., Moch H., Amin M., et al. Sarcomatoid differentiation in renal cell carcinoma: A study of 101 cases. Am J Surg Pathol 25 (2001) 275-284
62. Moch H., Gasser T., Amin M.B., et al. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: A Swiss experience with 588 tumors. Cancer 89 (2000) 604-614
63. Bertoni F., Ferri C., Benati A., et al. Sarcomatoid carcinoma of the kidney. J Urol 137 (1987) 25-28
64. Frank I., Blute M.L., Cheville J.C., et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol 168 (2002) 2395-2400
65. Lam J.S., Shvarts O., Said J.W., et al. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer 103 (2005) 2517-2525
66. Sengupta S., Lohse C.M., Leibovich B.C., et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 104 (2005) 511-520
67. Van Poppel H., Vandendriessche H., Boel K., et al. Microscopic vascular invasion is the most relevant prognosticator after radical nephrectomy for clinically nonmetastatic renal cell carcinoma. J Urol 158 (1997) 45-49
68. Goncalves P.D., Srougi M., Dall'lio M.F., et al. Low clinical stage renal cell carcinoma: Relevance of microvascular tumor invasion as a prognostic parameter. J Urol 172 (2004) 470-474
69. Uzzo R.G., Cherullo E.E., Myles J., et al. Renal cell carcinoma invading the urinary collecting system: Implications for staging. J Urol 167 (2002) 2392-2396
70. Palapattu G.S., Pantuck A.J., Dorey F., et al. Collecting system invasion in renal cell carcinoma: Impact on prognosis and future staging strategies. J Urol 170 (2003) 768-772
71. Terrone C., Cracco C., Guercio S., et al. Prognostic value of the involvement of the urinary collecting system in renal cell carcinoma. Eur Urol 46 (2004) 472-476
72. Fallick M.L., McDermott D.F., LaRock D., et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 158 (1997) 1691-1695
73. Zisman A., Pantuck A.J., Dorey F., et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19 (2001) 1649-1657
74. Kim H.L., Han K.R., Zisman A., et al. Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. J Urol 171 (2004) 1810-1813
75. Kim H.L., Belldegrun A.S., Freitas D.G., et al. Paraneoplastic signs and symptoms of renal cell carcinoma: Implications for prognosis. J Urol 170 (2003) 1742-1746
76. Symbas N.P., Townsend M.F., El-Galley R., et al. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 86 (2000) 203-207
77. Gogus C., Baltaci S., Filiz E., et al. Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 63 (2004) 447-450
78. Maldazys J.D., and deKernion J.B. Prognostic factors in metastatic renal carcinoma. J Urol 136 (1986) 376-379
79. Elson P.J., Witte R.S., and Trump D.L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48 (1988) 7310-7313
80. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296
81. Mekhail T.M., Abou-Jawde R.M., Boumerhi G., et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 832-841
82. Bukowski R.M., Negrier S., and Elson P. Prognostic factors in patients with advanced renal cell carcinoma: Development of an international kidney cancer working group. Clin Cancer Res 10 (2004) 6310S-6314S
83. Negrier S., Escudier B., Gomez F., et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Francais d'Immunotherapie. Ann Oncol 13 (2002) 1460-1468
84. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
85. Kattan M.W., Reuter V., Motzer R.J., et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166 (2001) 63-67
86. Zisman A., Pantuck A.J., Wieder J., et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20 (2002) 4559-4566
87. Patard J.J., Kim H.L., Lam J.S., et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: An international multicenter study. J Clin Oncol 22 (2004) 3316-3322
88. Cindolo L., Patard J.J., Chiodini P., et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: A multicenter European study. Cancer 104 (2005) 1362-1371
89. Vasselli J.R., Shih J.H., Iyengar S.R., et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci U S A 100 (2003) 6958-6963
90. Tan M.H., Rogers C.G., Cooper J.T., et al. Gene expression profiling of renal cell carcinoma. Clin Cancer Res 10 (2004) 6315S-6321S
91. Kim H.L., Seligson D., Liu X., et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10 (2004) 5464-5471
92. Kim H.L., Seligson D., Liu X., et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 173 (2005) 1496-1501
93. Lam J.S., Shvarts O., Leppert J.T., et al. Renal cell carcinoma 2005: New frontiers in staging, prognostication and targeted molecular therapy. J Urol 173 (2005) 1853-1862
94. Lam J.S., Leppert J.T., Figlin R.A., et al. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 66 (2005) 1-9
95. Harris A.L. Hypoxia-A key regulatory factor in tumour growth. Nat Rev Cancer 2 (2002) 38-47
96. Semenza G.L. HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med 8 (2002) S62-S67
97. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
98. Ohh M., Park C.W., Ivan M., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2 (2000) 423-427
99. Linehan W.M. Molecular targeting of VHL gene pathway in clear cell kidney cancer. J Urol 170 (2003) 593-594
100. Ivanov S., Liao S.Y., Ivanova A., et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158 (2001) 905-919
101. Lidgren A., Hedberg Y., Grankvist K., et al. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 11 (2005) 1129-1135
102. Bui M.H., Seligson D., Han K.R., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 9 (2003) 802-811
103. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11 (2005) 3714-3721
104. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 (1993) 1317-1320
105. Gnarra J.R., Tory K., Weng Y., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7 (1994) 85-90
106. Yao M., Yoshida M., Kishida T., et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 94 (2002) 1569-1575
107. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
108. Leppert J.T., Lam J.S., Yu H., et al. Targeting the vascular endothelial growth factor pathway in renal cell carcinoma, a tissue array based analysis. J Clin Oncol 23 suppl (2005) 386s
109. Lam J.S., Leppert J.T., Yu H., et al. Expression of the vascular endothelial growth factor family in tumor dissemination and disease free survival in clear cell renal cell carcinoma. In: J Clin Oncol 23 suppl (2005) 387s
110. Lane D.P. Cancer. p53, guardian of the genome. Nature 358 (1992) 15-16
111. Moch H., Sauter G., Gasser T.C., et al. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Urol Res 25 suppl 1 (1997) S25-S30
112. Zigeuner R., Ratschek M., Rehak P., et al. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: A systematic analysis of primary and metastatic tumor tissue. Urology 63 (2004) 651-655
113. Shvarts O., Seligson D., Lam J., et al. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol 173 (2005) 725-728
114. Vasavada S.P., Novick A.C., and Williams B.R. P53, bcl-2, and Bax expression in renal cell carcinoma. Urology 51 (1998) 1057-1061
115. Lee C.T., Genega E.M., Hutchinson B., et al. Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors. Urol Oncol 21 (2003) 179-184
116. Itoi T., Yamana K., Bilim V., et al. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. Br J Cancer 90 (2004) 200-205
117. Mizutani Y., Nakanishi H., Yamamoto K., et al. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol 23 (2005) 448-454
118. Srinivasula S.M., Datta P., Fan X.J., et al. Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway. J Biol Chem 275 (2000) 36152-36157
119. Migita T., Oda Y., Naito S., et al. Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer 94 (2002) 973-979
120. Hedberg Y., Ljungberg B., Roos G., et al. Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer 88 (2003) 1417-1423
121. Pantuck A.J., Seligson D.B., Wu H., et al. Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. J Urol 173 suppl (2005) 96
122. Seligson D.B., Pantuck A.J., Liu X., et al. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 10 (2004) 2659-2669
123. Herrem C.J., Tatsumi T., Olson K.S., et al. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res 11 (2005) 226-231